EM Imaging scores funding for cancer agents

By AuntMinnieEurope.com staff writers

December 17, 2019 -- Optical imaging agent developer Edinburgh Molecular Imaging (EM Imaging) has landed 3.1 million pounds (3.7 million euros) in financing to advance its molecular targeted systemic radiotherapy agents.

The Scottish company has developed the EMT-100 and EMT-101 therapeutic agents from its clinical stage imaging agent EMI-137, and it hopes to fast-track the new agents for radiotherapy treatments.

EMT-100 and EMT-101 feature peptides that target c-Met, which is overexpressed by many tumors compared to healthy tissue. The ultimate goal is to have the agents target several solid tumors and provide new treatment options for difficult-to-treat cancers, according to the company.

Copyright © 2019 AuntMinnieEurope.com

To read this and get access to all of the exclusive content on AuntMinnieEurope.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnieEurope.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking